FIELD: medicine.
SUBSTANCE: predicting in vitro an ability of a cartilage cell population to produce a stable hyaline cartilage in vivo of the cell population ensures determining an expression of a number of marker genes comprising a positive marker FRZB (Frizzled-like protein I), a negative marker ALK1 (Activine A Receptor, Type II-Like Kinase) and one or more markers specified in a group consisting of a negative marker PEDF (Pigment epithelium derived factor), a positive marker COL11 (Collagen, Type XI AI), a positive marker COL2 (Collagen, Type II. Alpha I) and a positive marker FGFR3 (Fibroblast growth factor receptor 3). The expression levels of each specific marker are presented by a numerical value. The numerical values are combined into a cumulative value, wherein the cumulative value shows an ability to produce the stable cartilage.
EFFECT: effective prediction of the ability of the cartilage cell population to produce the stable hyaline cartilage in vivo.
6 cl, 4 dwg, 11 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF CXCL6 CHEMOKINE DURING PREVENTION OR ELIMINATION OF CARTILAGE DEFECTS | 2004 |
|
RU2363491C2 |
| 3D IN VITRO TWO-PHASE OSTEOCHONDRAL CONSTRUCT | 2013 |
|
RU2615439C2 |
| METHOD OF PRODUCING CARTILAGE-LIKE STRUCTURES FROM STEM CELLS WITH INDUCED PLURIPOTENCY AND STRUCTURES OBTAINED USING SAID METHOD | 2023 |
|
RU2814248C1 |
| COMPOSITION FOR PREVENTION, RELIEF, OR TREATMENT OF DISEASES OR SYMPTOMS RELATED TO CARTILAGES, INCLUDING HAPLN1 | 2019 |
|
RU2788162C2 |
| TRANSIENT CELLULAR REPROGRAMMING TO REVERSE CELL AGING | 2019 |
|
RU2801316C2 |
| FGF-18 IN TRANSPLANTATION AND TISSUE ENGINEERING PROCEDURES | 2015 |
|
RU2682159C2 |
| METHODS AND COMPOSITIONS FOR TREATING DISEASE | 2007 |
|
RU2468820C2 |
| USING OPPOSITE CELL DIFFERENTIATION PROGRAMME (OCDP) FOR TREATING DEGENERATED ORGANS IN PATHOLOGICAL STATES | 2008 |
|
RU2528084C2 |
| METHODS OF PRODUCING INDUCED SMOOTH MUSCLE CELLS | 2020 |
|
RU2815906C2 |
| STROMAL STEM CELLS | 2013 |
|
RU2636551C2 |
